




The relative strengths and weaknesses of Xeris Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 9.3% points. The greatest weakness of Xeris Biopharma Holdings Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 73% points below the market average of 213%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	156,264	Assets	322,602
Cost of Goods Sold	0	Liabilities	329,384
Intangible Assets	132,623	Expenses	206,675
Liabilities, Current	95,193	Revenues	163,914
Liabilities, Non-Current	39,612	Stockholders Equity	-6,782
Other Assets	27,744	Net Income	-62,255
Other Compr. Net Income	-2.0	Comprehensive Net Income	-62,256
Other Expenses	38,239	BaseVar	521,036
Other Liabilities	194,579	ECR before LimitedLiability	-24%
Other Net Income	-19,494	Economic Capital Ratio	140%
Other Revenues	163,914		
Property and Equipment	5,971		
Research and Development	22,341		
Selling, General and Administrative Expense	146,095		